Skip to main navigation Skip to search Skip to main content

Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer

  • Fox Chase Cancer Center
  • Brown University

Research output: Contribution to journalArticlepeer-review

35 Scopus citations

Fingerprint

Dive into the research topics of 'Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome, Metastatic Colon, and Localized Urothelial Cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry